Last reviewed 2026-04-23 · How we verify

TVR

TVR is a protease inhibitor that works by blocking the replication of the hepatitis C virus.

TVR is a protease inhibitor that works by blocking the replication of the hepatitis C virus. Used for Chronic hepatitis C, Hepatitis C genotype 1 infection.

At a glance

Mechanism of action

TVR is a non-nucleoside inhibitor of the NS5B polymerase, which is essential for the replication of the hepatitis C virus. By blocking this enzyme, TVR prevents the virus from replicating and reduces the viral load in the body.

Approved indications

• Chronic hepatitis C
• Hepatitis C genotype 1 infection

Common side effects

• Fatigue
• Headache
• Nausea
• Diarrhea
• Abdominal pain

Key clinical trials

• Safety and Effectiveness of the Crystalline Sirolimus-Eluting Device in Patients With Coronary Artery Disease
• Evaluation of Patients With Hypertensive Disorders of Pregnancy: An Ambispective Observational Study
• RESOLUTE ONYX China RCT Study (NA)
• RESOLUTE ONYX China Single Arm Study (NA)
• WBV Reflex Latency and Mechanical Load (NA)
• Laparoscopic Ventral Mesh Rectopexy Versus Trans-vaginal Repair for Anterior Rectocele. (NA)
• Surgical Treatments of Tricuspid Valve Regurgitation After Cardiac Surgery
• China Resolute Integrity 34/38 mm Study (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• TVR CI brief — competitive landscape report
• TVR updates RSS · CI watch RSS
• Janssen R&D Ireland portfolio CI